Hospital-acquired and Ventilator-Associated Pneumonia
Key Points
Key Points
All-cause mortality associated with VAP has been reported to range from 20%–50%.
Serious complications from HAP occur in approximately 50% of patients.
Diagnosis
Diagno...
...Factors for Multidrug-Resistant Pathogens...
...crobiologic Met...
...IDSA suggest noninvasive sampling with semiquanti...
...sive sampling with semiquantitative cul...
...suggest that patients with suspected HAP...
...markers...
...or patients with suspected HAP/VAP, ATS and IDSA r...
...atients with suspected HAP/VAP, ATS and IDSA re...
...ents with suspected HAP/VAP, ATS and IDSA reco...
...ith suspected HAP/VAP, ATS and IDSA su...
Treatment
Treatme...
Initia...
...ventilator-associated tracheobronc...
...IDSA recommend that all hospitals regula...
...ecommend that empiric treatment regimens be i...
...ith suspected VAP, ATS and IDSA reco...
...DSA suggest including an agent active ag...
...IDSA suggest including an agent active agains...
...f empiric coverage for MRSA is indicated,...
...ric treatment that includes coverage for MSSA (an...
...gest prescribing two antipseudomona...
...nd IDSA suggest prescribing one antibio...
...th suspected VAP, ATS and IDSA suggest...
...tients with suspected VAP, ATS and I...
...IDSA recommend that empiric antibiotic regi...
...IDSA recommend that all hospitals...
...ts being treated empirically for HAP, ATS and IDS...
...with HAP who are being treated empiricall...
...with HAP who require empiric coverage for M...
...with HAP who are being treated empiricall...
...r patients with HAP who are being treated empirica...
...ents with HAP who are being treated empiri...
...h HAP who are being treated empirically, AT...
Optimizatio...
...patients with HAP/VAP, ATS and IDSA suggest that...
...ed Antibiotic
...th VAP due to Gram-negative bacilli...
...thogen-Specific Ther...
...recommend that MRSAHAP/VAP be treated with...
...nts with HAP/VAP due to P. aerugino...
...ients with HAP/VAP due to P. aerugi...
...atients with HAP/VAP due to P. aeru...
...th HAP/VAP due to P. aeruginosa who r...
...atients with HAP/VAP due to P. aerugino...
...patients with HAP/VAP due to extended-spect...
...ts with HAP/VAP caused by Acinetobacter...
...ts with HAP/VAP caused by Acinetobacter species...
...ATS and IDSA suggest adjunctive inhale...
In patients with HAP/VAP caused by A...
...patients with HAP/VAP caused by Acinetobacte...
...ith HAP/VAP caused by a carbapenem-resi...
and ATS and IDSA suggest adjunctive inhale...
...s with VAP, ATS and IDSA recommend...
...nts with HAP, ATS and IDSA recommend a 7...
...ients with HAP/VAP, ATS and IDSA suggest...
...ts with HAP/VAP, ATS and IDSA sugge...
...h suspected HAP/VAP, ATS and IDSA suggest NOT us...
...2. Recommended Initial Empiric Antibiotic T...
...piric Treatment Options for Suspecte...